Summary Early and severe loss of body weight associated with pronounced tissue changes developed in rats transplanted with a fast-growing ascites hepatoma (Yoshida AH-130). The protein content showed an early and marked fall in the skeletal muscle, while in the liver it transiently increased 4 days after implantation then declined to values lower than in control animals. Protein loss in gastrocnemius muscle and liver resulted mainly from enhancement of protein catabolism (Tessitore L. et al., Biochem. J., 241: 153-158, 1987). In contrast to the tumour-bearing rats, in the pair-fed animals the initial body weight was maintained, while the protein mass decreased sharply in the liver and moderately in the grastrocnemius muscle. In host animals total plasma protein decreased during the period of tumour growth, while both triglycerides and total cholesterol markedly increased. Glucose remained unchanged even when overt cachexia had developed. The total free amino acid concentration in the plasma of tumour-bearing rats decreased slightly by day 4 and returned to values close to those of controls in the late stages of tumour growth. By contrast, in the pair-fed controls the plasma levels of triglycerides and particularly of total free amino acids and glucose decreased over the whole experimental period, whereas total protein and cholesterol were unchanged. Marked perturbations in the hormonal homeostasis developed early after tumour transplantation. The plasma levels of glucagon, corticosterone and catecholamines rose sharply, while those of insulin and thyroid hormones decreased. Furthermore, high plasma concentrations of prostaglandin E2 (PGE2) and tumour necrosis factor (TNF) were observed over the whole experimental period. IL-I-like activity, TNF and PGE2 were released in vitro from AH-130 cells. These data suggest that the systemic effects of AH-130 tumour on the host rat reflected the interplay of a complex network of factors, including classical hormones and cytokines, all of which likely concur in enhancing tissue protein catabolism.
Cachexia frequently accompanies advanced or terminal cancer states, though it can also develop early in the course of neoplastic diseases (Shapot, 1979; Lawson et al., 1982; Kern & Norton, 1988; Morrison, 1989) . The underlying mechanisms are not well understood, either in humans or in experimental animals.
In the early phases of tumour growth the total protein mass of the body is usually preserved, even though nitrogen can be already redistributed out of host tissues and diverted to the tumour (Lawson et al., 1982) . In overt cachexia, loss of lean body weight primarily reflects waste of tissue proteins, particularly from skeletal muscles (which account for almost half of the protein mass in the body). Tissue protein waste implies a negative balance between anabolic and catabolic processes. In this regard hypophagia and proteincalorie malnutrition can play an important role (Kern & Norton, 1988; Morrison, 1989 ), yet most often parenteral or over-feeding are only transiently and partially effective in combating cancer cachexia (Theologides, 1972; Bozzetti et al., 1987) . The view that protein depletion may primarily reflect enhanced protein turnover has been recently supported by both experimental (Tayek et al., 1986 (Tayek et al., , 1988 Tessitore et al., 1987a; Beck & Tisdale, 1989) and clinical evidence (Kien & Camitta, 1983 Fearon et al., 1988; Melville et al., 1990; Beck et al., 1991) .
We have previously shown that growth of the ascites hepatoma Yoshida AH-130 in rats elicits an early and conspicuous loss of body weight, associated with a protein hypercatabolic state in host tissues (Tessitore et al., 1987a) . The initial changes are already manifest at a tumour burden not exceeding 0.1% of the host body weight; this figure is significantly lower than the tumour burden usually observed to cause cachexia in most experimental models, yet not far from that observed in humans (cf. Morrison et al., 1984; Pisters & Brennan, 1990 ). This experimental model thus appears particularly appropriate to investigate the mechanisms involved in tumour associated cachexia.
In the present study we have evaluated some systemic effects of the Yoshida AH-130 tumour on the host, focusing on factors which may affect tissue protein metabolism. We report here that marked perturbations in the hormonal homeostatis and occurrence of cytokine-like factors are elicited soon after implanting the AH-130 tumour. Moreover, the tumour cells themselves are able to release cytokines such as TNF and IL-l as well as PGE2. All these events are likely to play a significant role in forcing protein metabolism in host tissues into a hypercatabolic state. Therefore, the present data further support the hypothesis (Tessitore et al., 1987a) that protein depletion in these tumour hosts mainly reflects an 'active' loss rather than just impoverishment due to reduced food uptake or metabolic competition by the tumour.
Material and methods

Animals and tumours
Male Wistar rats (Nossan, Milano, Italy) weighing about 200 g were maintained on a regular light-dark cycle (light 08:00-20:00) and had free access to a balanced semi-synthetic diet (Piccioni, Brescia, Italy) and water. The Yoshida ascites hepatoma AH-130 was maintained by weekly intraperitoneal transplantation of approx. 3 10' cells, while for the experiments rats were injected with 108 cells from exponential tumours (Tessitore et al., 1987a) . The animals were divided into two groups (ad libitum fed controls and transplanted) of comparable body weight. In some experiments, a third group of pair-fed controls was added. The amount of food consumed by individually housed rats was calculated every day by weighing the food that remained by 12 a.m. Skin and and cellularity were measured. In some experiments tissues were homogenised to 1:10 (w/v) in chilled distilled water with a Turrax apparatus (Janke & Kunkel, Ika-Werk, Staufen, Germany), then sonicated (2 x 30 s), centrifuged at 4°C and frozen in aliquots at -80°C. Samples used for amino acid determination were previously deproteinised with sulphosalicyclic acid.
Assays
Protein was determined as previously reported (cf. Baccino et al., 1982) , triglycerides with the kit Triglycerides GPO Reagent (Biorad, Richmond, CA, USA), glucose with the kit Glu-Cinet (Sclavo S.p.a., Siena, Italy), calcium with the Unikit II (Roche, Basel, Switzerland), and total cholesterol with a kit from Boehringer, Mannheim, Germany. Amino acids were evaluated using an amino acid analyser (Kontron Instruments, Zurich, Switzerland) by the method of Moore & Stein (1951) . Blood plasma hormones were measured by radioimmunoassay using commercially available kits: Insulin radioimmunoassay (Corning, Medfield, MA, USA), total T3 and T4 (Lepetit, Milano, Italy), Ria-mat Glucagon (Mallinckrodt, Dietzenbach, Germany). Corticosterone was evaluated by a competitive protein-binding assay (Angeli et al., 1975) . Free catecholamines in plasma and urine were determined by HPLC using a kit from Biorad, Richmond, CA, USA. To assay PGE2, prostanoids were separated by HPLC (Nigan et al., 1985) . TNF was determined either by an ELISA test (Genzyme, Cambridge, MA, USA) or with the L929 cell toxicity assay (Flick & Gifford, 1984) ; one unit of activity was defined as the reciprocal dilution required to produce a 50% decrease in absorbance relative to control cells exposed to actinomycin D alone. IL-1 activity was measured using the mouse thymocyte proliferation assay (Cannon & Dinarello, 1985) ; one unit of activity was defined as the reciprocal of the dilution required to produce a 50% increase in stimulation index relative to thymocytes exposed to phytohaemagglutinin alone.
Cell cultures
Peripheral blood monocytes/macrophages, isolated from control and tumour-bearing rats as previously reported (Tessitore et al., 1987b) , were cultured for 24 h in RPMI medium containing 10% FCS in the presence or in the absence of 5 fig ml-' of E. coli LPS (Sigma, St. Louis, MO, USA) . At the end of the incubation the culture medium was tested for the presence of IL-1 and TNF bioactivities.
Short term cultures of AH-130 tumours were performed with cells harvested from animals under sterile conditions, washed, resuspended in DMEM containing 10% FCS at the concentration of 106 ml-', and incubated for 24 h at 370C.
The culture medium was then collected and IL-i-like activity and TNF measured; 20 mM indomethacin was added to the samples used to evaluate the PGE2 production. In some experiments, the inflammatory cells contaminating the ascites tumour were separated by adhesion to a glass surface as previously reported (Tessitore et al., 1987c) ; the two populations thus obtained, namely, peritoneal macrophages and AH-130 cells, were incubated as described above.
The release of PGE2 from muscle was evaluated incubating the soleus in the extended position for 3 h in Krebs-Ringer bicarbonate buffer at 370C. To block de novo synthesis of PGE2, 20 mM indomethacin was added at the end of the incubation and the samples frozen.
Statistical analysis Data are presented as means ± s.d. The significance of differences has been evaluated by analysis of variance.
Results
Body and tissue weight As previously reported (Tessitore et al., 1987a) , with an intraperitoneal inoculum of 108 cells the tumour maintained exponential growth for about 6 days; growth then subsided, attaining a quasi-stationary phase by day 8 (Figure 2a) . Death of the animals occurred about 15 days after transplantation. In the present work two time points were selected for most experiments; day 4, for the middle of the log phase of tumour growth, and day 10, for the fully established stationary phase. The daily food intake per animal amounted to 18-20 g for ad libitum fed controls, but after tumour implantation it gradually declined from 18 g on day 0 to about 10 g on day 10 (then dropping to 3 g on day 12 and about 0 g at day 14). The water intake was quite similar (about 25 ml/day) for controls and tumour-bearing animals over the whole experimental period. Thus in many experiments we included a third group of rats, the pair-fed controls, which received food in the same amount as ingested by tumour bearers.
In tumour-bearing rats the body weight, excluding the ascites tumour, steadily declined to about half the control values on day 10 (Figure 1 ). In the present study we focused our attention on two tissues that showed the most prominent changes (cf Tessitore et al., 1987a) : the gastrocnemius muscle (Figure 2c) , showing a progressive, marked fall in protein content, and the liver (Figure 2b ), which manifested first a rise, then a fall in protein content. Gastrocnemius wasting and changes in other tissues (data not shown) were already manifest when the tumour mass attained approximately 0.1% of the body weight (day 2), while severe cachexia developed at day 10, when the tumour burden approximated 5% of the body weight.
Additional information on the metabolic state of tumour hosts is provided by data shown in Figures values close to those of controls when the animals were most cachetic. Total cholesterol ( Figure 3 ) showed a sustained and progressive increment in the blood plasma, in agreement with previous observations (Grunfeld et al., 1989; Stovroff et al., 1989) ; this increase has been shown to be associated with elevation of low-density lipoprotein cholesterol and reduction of high-density lipoprotein cholesterol (Dessi et al., 1992) . The steady increase in triglycerides ( Figure 3 ) was consistent (cf. Beutler & Cerami, 1988; Sherman et al., 1988; Sherry et al., 1989) with the observed sustained increase of TNF in tumour-bearing animals (see below). Also suggesting a release of cytokines was the increase of the rectal (Table I) and skin (not shown) temperature during the first days after tumour transplantation, although this was followed by a progressive fall to subnormal values in later stages.
In the group of pair-fed controls, undernutrition was severe enough to cause significant metabolic changes. The rats did not gain body weight during the experimental period ( Figure 1 ). The gastrocnemius muscle also sustained some protein loss, though much less pronounced than in tumour bearers ( Figure 2c) ; the hepatic protein mass markedly decreased, reaching values that at day 10 were even lower than in tumour bearers (Figure 2b ). The protein-calorie restriction also caused a persistent hypoglycemia (Figure 3 ), in contrast with the normal values in tumour bearers. Total free amino acids (Figure 4) were slightly decreased in the pair-fed controls, while in tumour hosts plasma amino acids returned to normal levels at day 10. Triglycerides ( Figure 3) slightly declined in the pair-fed group, but were markedly elevated in tumour bearers. Finally, the pair-fed rats did not develop any significant alteration in the blood plasma levels of protein and cholesterol (Figure 3 ), contrasting with their falling and rising pattern, respectively, in tumour hosts.
Hormones and other humoralfactors Several hormones and other humoral agents are known to be potential modifiers of protein metabolism in peripheral tissues (Waterlow, 1984) and thus are possible candidates as positive or negative effectors of the hypercatabolic state in AH-130 tumour hosts. The blood plasma levels of a number of such agents after tumour implantation in rats are listed in Table I , showing that multiple and pronounced alterations of the endocrine status developed in these animals. Insulin markedly declined to less than half of the normal values by day 4 and remained at this level until the end of the experimental period (as predictable, it was also reduced in pair-fed animals [data not shown; cf. Lagopoulos et al., 1991] ). Reciprocally, by day 4 glucagon reached values 4-6-fold higher than in controls. T3 and, particularly, T4 were reduced by day 3, down to about half and one fourth of control values, respectively. Corticosterone was elevated by day 4, but returned to control levels on day 10. The plasma levels of norepinephrine and epinephrine were markedly increased by day 4 and even more so at day 10. The concentration of free urinary catecholamines showed a progressive increase up to day 9 ( Figure 5) .
TNF was detected both as bioactivity (data not shown) and as immunoreactive protein in the plasma of tumourbearing rats since the first day after transplantation, peaking at day 4 (Table I ; assay sensitivity about 1O pg ml-'). PGE2, a putative enhancer of muscle protein catabolism (Rodemann & Goldberg, 1982a; Strelkov et al., 1989) , was also increased (Table I ). Calcium has also been suggested to stimulate muscle protein catabolism (cf. Rodemann et al., 1982b) : its increase in the blood plasma has been observed in animals after treatment with IL-1 and TNF (Sabatini et al., 1988 (Sabatini et al., , 1990 and in cancer patients (Tashjian et al., 1974) ; we did not, however, detect any change in calcium in AH-130 tumour hosts (Table I) .
Further experiments were designed to determine the cellular origin of plasma TNF and PGE2 in tumour-bearing rats. Two possible sources were considered: (1) circulating and peritoneal mononuclear phagocytes or (2) the tumour cells themselves. As shown in Table II , the presence of the tumour at day 4 did not modify the ability of blood monocytes to release TNF in vitro upon challenge with LPS, yet strongly depressed it at day 10; on the other hand, blood monocytes at day 4 released TNF even when cultured in the absence of LPS, suggesting some degree of cell activation. By contrast, the release of IL-1 was not affected, either in the presence or in the absence of LPS (Table II) . As for the alternative hypothesis, the AH-130 hepatoma cells released appreciable amounts of PGE2 (Figure 6 ), in agreement with previous reports (Strelkov et al., 1989; Trevisani et al., 1980; also see Tanaka et al., 1989) . Of special interest was the finding that in short-term culture these tumour cells released significant amounts of TNF as well as of IL-1 (Figure 6 ). This release was higher for exponential than for stationary tumour cells, while the release of PGE2 showed an opposite pattern ( Figure 6 ). Consistently, TNF could be detected in the ascitic fluid at concentrations higher at day 4 than at day 10 (143 ± 9 and 49 ± 5 pg ml-, respectively). Because reactive leukocytes are an ordinary contaminant of this ascites tumour, amounting to about 5% in the first days of growth (cf. Tessitore et al., 1987c), we measured their contribution to the observed release of cytokines. As shown in Table III, less than half that of controls (Figure 7 ), in agreement with a previous report (Strelkov et al., 1989) . however, the production of IL-1 activity and TNF by purified macrophages separated from the whole ascites tumour at day 4 was considerably lower than that by the tumour cells alone. It can be noted that the release of TNF from peritoneal macrophages (Table III) was of the same order of the spontaneous release from blood monocytes at day 4 (Table II) , while the release of IL-1 from peritoneal macrophages (Table III) animals under the influence of a variety of cancers (Kern & Norton, 1988; Theologides, 1972) . Studies performed on mice bearing the MAC16 colon adenocarcinoma, a cachexiainducing tumour, have shown an elevated nitrogen loss during early tumour growth (Beck & Tisdale, 1989) . Moreover, a number of reports have pointed out that enhanced tissue protein degradation or acceleration in whole body protein turnover make a substantial contribution to the protein waste in tumour-bearing patients (Kien & Camitta, 1983 Fearon et al., 1988; Melville et al., 1990; O'Keefe et al., 1990) and experimental animals (Tayek et al., 1986 (Tayek et al., , 1988 AH-130 cells clearly have the ability to grow, or at least to maintain a stationary state, though overall in the host protein catabolism predominates, particularly in some tissues. Thus, the protein metabolic perturbations in the host, while causing tissue waste, may as a consequence favour the tumour growth by providing the necessary nitrogen for protein in the tumour (cf. Beck et al., 1991) .
After AH-130 tumour implantation, the food intake of the host rats progressively declined. Although such a decline was sufficient to cause significant metabolic alterations in pair-fed controls, the resulting overall pattern was quite different from that in tumour hosts. Pair-fed controls developed a typical pattern of partial starvation (Waterlow et al., 1978; Baccino et al., 1982; Arnal et al., 1987) , presenting with relative loss of body weight (no body weight change compared to the gain in ad libitum-fed animals), actual protein loss from both gastrocnemius muscle and liver, and persistently reduced plasma concentrations of glucose and total free amino acids. In tumour-bearing animals, however, the body weight progressively declined, protein loss in the gastrocnemius was considerably more pronounced, total liver protein first increased at day 4 and then declined at day 10, yet remaining higher than in pair-fed controls. Moreover, tumour hosts did not develop hypoglycemia, at least until day 10, and their plasma concentration of total free amino acids, though initially decreased, returned to normal levels by day 10. Plasma lipids also showed marked differences, triglycerides and total cholesterol being increased in tumour hosts only. On the basis of such observations, hypophagia should be ruled out as a major determinant of the metabolic patterns that characterise AH-130-bearing rats, at least in early stages. Yet undernutrition undoubtedly occurs in these tumour hosts, thus adding a further component to the complexity of their metabolic perturbations. Studying a different model of cachexia, Mulligan & Tisdale (1991) have recently shown that only tumour-bearing animals that failed to adjust their food intake in the presence of metabolic disturbances underwent dramatic weight loss.
Humoral mediators
Altered hormonal levels as well as factors produced by host or tumour cells likely combine to cause cancer cachexia. Some of the systemic effects in cancer hosts have been ascribed to non-dialyzable circulating lipolytic and proteolytic factors produced by the tumour (Beck & Tisdale, 1987; Beck et al., 1990) , which is consistent with the parabiotic transfer of cachexia reported by Norton et al. (1985) . High plasma levels of catabolic hormones, low levels of insulin, and insulin resistance of peripheral tissues are among the factors most commonly considered as a cause of cancer cachexia (Lawson et al., 1982; Morrison, 1989) . However, it has been suggested that hormonal changes could rather reflect an adaptation to the metabolic alterations that lead to cachexia (Svaninger et al., 1987a,b,c) . In rats bearing the AH-130 tumour a whole spectrum of hormonal alterations have been observed which may enhance tissue protein degradation: insulin was decreased (cf. Goodlad et al., 1975) while counter-regulatory hormones such as corticosterone (cf. Goldberg, 1969; Odedra & Millward, 1984; Legaspi et al., 1985) , glucagon (cf. Kibler et al., 1964) and catecholamines (cf. Van Gool et al., 1984) were elevated. The high level of corticosterone at day 4 well correlated with enlarged adrenal glands and an associated hypertrophic/hyperplastic histological pattern. As an apparent exception to the hypercatabolic endocrine pattern, the low plasma concentrations of thyroid hormones might be expected to play an opposite role (Morrison et al., 1988) . However, a reduction of T3 and T4 does not necessarily imply a decrease in thyroid biological activity, as shown by Kumara-Siri et al. (1981) : rats bearing the Walker 256 carcinoma have low concentrations of T3 and T4, while maintaining normal TSH concentrations.
Cytokines such as TNF and IL-1, released by macrophagic cells, have been proposed as the main mechanism for cancer cachexia (Beutler & Cerami, 1988; Mahony & Tisdale, 1988; Evans et al., 1989; Fong et al., 1989) . Repeated administration or chronic infusion of TNF Michie et al., 1989; Darling et al., 1990) or IL-1 induces significant anorexia, weight loss, and loss of body protein in rats and cachexia has been observed in nude mice inoculated with CHO cells rendered TNF-producer by transfection with human TNF cDNA (Oliff et al., 1987) . The observations concerning the presence of TNF and IL-1 in the serum of cancer patients are inconsistent, however. Moldawer et al. (1988) could not detect IL-1 and TNF bioactivities in the plasma of weight-losing cancer patients; other investigators have made similar observations (Scuderi et al., 1986; Waage et al., 1986; Selby et al., 1987; Socher et al., 1988b) . By contrast, the presence of TNF has been observed in the serum of children with acute lymphoblastic leukaemia (Saarinen et al., 1990) , in other cancer patients (Aderka et al., 1985; Balkwill et al., 1987) , and in cachectic tumourbearing rats (Stovroff et al., 1989) . In our studies a fairly constant elevation of TNF was detected in the plasma of AH-130-bearing rats at days 4 and 10, indicating that there was no apparent correlation with the tumour burden (at variance with previous observations on sarcoma-bearing rats [Stovroff et al., 1989] ).
In short term cultures the AH-1 30 hepatoma cells released PGE2 (cf. Trevisani et al., 1980; Strelkov et al., 1989) , IL-1-like factors, and TNF. The release of cytokines was higher in the exponential phase of growth, and thus positively correlated with the cell proliferation rate; consistently, TNF was more elevated at day 4 than at day 10 both in the ascitic fluid and in the blood plasma. Contrariwise, the release of PGE2 from AH-130 cells (and its plasma concentration as well) was more elevated in the stationary phase; whether this finding * implies some kind of mutual regulation between PGE2 and cytokines (Goldings, 1986; Candela et al., 1991) was not investigated. In addition, some IL-1 and TNF were produced by ascites macrophages, while blood monocytes from tumour-bearing rats spontaneously released TNF. The possibility that such activation of mononuclear phagocytes was triggered by cytokines (Platanias & Vogelzang, 1990; Jiiattela, 1991) originating from tumour cells should be considered. In AH-130 tumour hosts plasma PGE2 was elevated and circulating TNF was detectable; although we failed to demonstrate a corresponding elevation of IL-1 activity (data not shown), the possibility that such activity was masked by inhibitors or soluble cytokine receptors in the blood plasma (Symons & Duff, 1991 ) cannot be excluded. This consideration also applies to TNF (Gatanaga et al., 1990; Aderka et al., 1991 and , the levels of which might have been underestimated. Other workers (Gelin et al., 1991) have made partially similar observations: TNF and IL-1 are produced by a tumour of non-lymphoid origin, the undifferentiated sarcoma MCG 101, which causes cachexia in mice and also elicits an acute phase response, yet no plasma elevation of either cytokine could be demonstrated. Our present and previous work (Tessitore et al., 1987a) , on the other hand, has clearly established that the AH-1 30 tumour quickly elicited in the host rat an array of changes which are among those characteristic of TNF and/or IL-1, such as increased hepatic uptake and muscular release of amino acids with reduced plasma levels of amino acids (Starnes et al., 1988; Argiles et al., 1989) , acceleration of whole body protein turnover (Starnes et al., 1988) , increased degradation and depletion of muscle protein (Baracos et al., 1983; Tracey et al., 1988; Fong et al., 1989; however, see: Kettlehut & Goldberg, 1988) , transient liver hyperplasia (Feingold et al., 1988; Fong et al., 1989; Mealy et al., 1990) , augmented plasma levels of triglycerides (Feingold & Grunfeld, 1987; Starnes et al., 1988; Grunfeld et al., 1989) , increased hepatic synthesis and serum levels of cholesterol (Feingold & Grunfeld, 1987) . TNF or IL-1 can also activate a variety of other mechanisms and cause the elevation of plasma mediators such as cathecholamines and glucagon (Starnes et al., 1988; Rivier et al., 1989) , cortisol or corticosterone and ACTH (Del Rey & Besedowsky, 1987; Starnes et al., 1988; Kehrer et al., 1988; Tracey et al., 1988; Argiles et al., 1989; Rivier et al., 1989; Sharp et al., 1989) and PGE2 (Dayer et al., 1985) . By contrast, serum T3 and T4 decline after TNF and were decreased in AH-130 tumour-bearers.
The role of cytokines in cancer cachexia may appear questionable in view of the observation that the administration of a single cytokine renders most animals refractory to its effects (Mahony & Tisdale, 1988; Socher et al., 1988a; Stovroff et al., 1989; Tracey et al., 1988; Grunfeld et al., 1989; Darling et al., 1990) . This would imply, at least, that single cytokines must act in concert with other cytokines or factors (Michie et al., 1989) for cancer cachexia to develop. On the other hand, cachexia could be attenuated in MCG 101 sarcoma-bearing mice with anti-TNF antibodies (Sherry et al., 1989) or in rats transplanted with a methylcholanthrene-induced sarcoma by eliciting tolerance to TNF through repeated administration of this cytokine at low dosage (Sheppard et al., 1990) . Besides the MCG 101 sarcoma (Gelin et al., 1991) and the AH-130 hepatoma, also the Ehrlich ascites tumour cells produce TNF and circulating TNF can be detected in the host mice (Tessitore L., Costelli, P., Baccino, F.M., unpublished data). These observations are of special interest since cytokine production by tumours was previously known only for leukaemic cells (e.g., Platanias & Vogelzang, 1990; Aguilar-Santelises et al., 1991) . Thus for a few experimental tumours, among those having the ability to elicit a rapidly progressive cachexia, the host-wasting properties seem associated, at least in part, with their ability to release significant amounts of cytokines, such as IL-1 and TNF (and possibly of other factors such as PGE2).
Concluding remarks
The primary causative factors involved in the profound metabolic perturbations that lead to cancer-induced cachexia remain largely elusive as yet. Many different mechanisms have been cited in different situations, either in humans or in experimental models. In the present study a number of potentially relevant parameters have been found to be altered in rats bearing the AH-130 Yoshida ascites hepatoma and further work is needed to clarify which, among them, may have an initiating role. In any event, there seems no doubt that cancer cachexia in the present model reflects complex homeostatic perturbations and develops through the interplay of multiple factors (hormone changes, production of cytokines, hypophagia), virtually all which seem to converge in forcing protein metabolism, particularly in skeletal muscle, into a hypercatabolic state.
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